Inventiva Pharma welcomed Chris Benecchi as Chief Operating Officer.
Published
Signal category
People
Quote
“We're pleased to welcome Chris Benecchi to Inventiva as our Chief Operating Officer!”
— Inventiva Pharma team
Company
Inventiva Pharma
A clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies.
- Industry
- Biotechnology Research
- Location
- Daix, FR
- Company size
- 125 employees
At Inventiva, we are united in developing differentiated treatments for MASH and making a meaningful difference in the lives of those affected. Recognizing that MASH is not just a liver disease but also a cardiometabolic condition, we have purposefully designed a potential oral therapy — currently in clinical development — intended to restore metabolic balance at the source and directly target inflammation and fibrosis. Our goal is to bring relief to patients across the MASH patient population, addressing a critical unmet need in a progressive and life-threatening disease. Our product candidate, lanifibranor, has been granted FDA Breakthrough Therapy Designation and is now being evaluated in a global Phase 3 clinical trial.
Founded 2012